PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10386468-6	1999	This study was designed to assess the effects of finasteride on the expression levels of bFGF, FGFR1, and FGFR2 in patients with BPH.	Finasteride	49-60	fibroblast growth factor 2	Homo sapiens	89-93	
17921535-1	2007	The results of our study showed, that long-term combined medical treatment of benign prostatic hyperplasia (Finasteride 5 mg/day + Tamsulosin 0.4 mg/day) significantly decreases values of IPSS and residual urine volume (RUV) in patients, which basic level of bFGF in serum does not exceed 5.9 pg/ml.	Finasteride	108-119	fibroblast growth factor 2	Homo sapiens	259-263	
10386468-7	1999	METHODS: The expression levels of bFGF, FGFR1, and FGFR2 in 9 patients with prostatic hyperplasia treated with finasteride were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) analysis of mRNA expression and were compared with those of 9 control patients with untreated BPH.	Finasteride	111-122	fibroblast growth factor 2	Homo sapiens	34-38	
10386468-15	1999	CONCLUSIONS: A marked reduction in bFGF levels is seen in BPH treated with finasteride in comparison to untreated BPH.	Finasteride	75-86	fibroblast growth factor 2	Homo sapiens	35-39	
10386468-16	1999	In our opinion, finasteride may act as a negative regulator of bFGF expression, counteracting the role of bFGF in the development of BPH.	Finasteride	16-27	fibroblast growth factor 2	Homo sapiens	63-67	
10386468-16	1999	In our opinion, finasteride may act as a negative regulator of bFGF expression, counteracting the role of bFGF in the development of BPH.	Finasteride	16-27	fibroblast growth factor 2	Homo sapiens	106-110